Nicholas Brodszki
1 – 15 of 24
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
First year of TREC-based national SCID screening in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline : Deficiencies, Diagnosis, and Management
2020) In Journal of Clinical Immunology(
- Contribution to journal › Article
-
Mark
Add-on or alone? Inhaled nebulized immunoglobulin reduces upper airway infections : 24 months of real-life experience
(
- Contribution to journal › Article
-
Mark
Definition, aims, and implementation of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence
(
- Contribution to journal › Article
- 2019
-
Mark
Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies
(
- Contribution to journal › Article
-
Mark
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents
(
- Contribution to journal › Article
- 2018
-
Mark
Kappa-deleting recombination excision circle levels remain low or undetectable throughout life in patients with X-linked agammaglobulinemia
(
- Contribution to journal › Article
- 2017
-
Mark
Screening protocols to monitor respiratory status in primary immunodeficiency disease : findings from a European survey and subclinical infection working group
(
- Contribution to journal › Article
-
Mark
Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20%
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.217-217(
- Contribution to journal › Published meeting abstract
-
Mark
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.216-216(
- Contribution to journal › Published meeting abstract
-
Mark
Best Possible Treatment for All Patients with Primary Immune Deficiency (PID) in Sweden Regardless of Social Factors, Sex, Age or Residence
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.249-249(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.
(
- Contribution to journal › Article
-
Mark
Primary immunodeficiency in southern Sweden. Strategies for diagnosis and clinical management
(
- Thesis › Doctoral thesis (monograph)
-
Mark
Pulmonary and pleural lymphatic endothelial cells from pediatric, but not adult, patients with Gorham-Stout disease and generalized lymphatic anomaly, show a high proliferation rate
(
- Contribution to journal › Article
-
Mark
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2 : A cohort study
(
- Contribution to journal › Article